BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 28603915)

  • 1. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma].
    Cai YL; Li J; Lu AY; Zhong WM; Zheng YM; Gao JQ; Zeng H; Chen WS; Liang W; Tang MZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):119-22. PubMed ID: 24044217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J; Cui Z; Zheng Y; Li X; Chen Y
    Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of Serum Epstein-Barr Virus Capsid Antigen-IgA for Nasopharyngeal Carcinoma: a Meta-Analysis Based on 21 Studies.
    Chen Y; Xin X; Cui Z; Zheng Y; Guo J; Chen Y; Lin Y; Su G
    Clin Lab; 2016; 62(6):1155-66. PubMed ID: 27468579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between environmental factors and serological Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma in South China.
    Zhou T; Yang DW; He YQ; Xue WQ; Liao Y; Zheng MQ; Jia YJ; Yuan LL; Zhang WL; Zeng YX; Jia WH
    Cancer Med; 2019 Aug; 8(10):4852-4866. PubMed ID: 31241250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
    Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
    Shimakage M; Dezawa T; Chatani M
    Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.